Q2 FY2026 · ended Jun 30, 2026 · Revenue $7.19M, +11.5% YoY · Filed Aug 13, 2026
ImmuCell Corporation (ICCC) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $7.2 million and net income of $1.8 million. Free cash flow was $2.3 million. As of Jun 30, 2026 it held $8.9 million in cash and investments and $12.4 million in total debt.
Revenue
$7.19M
+11.5% vs year-ago quarter
Net income
$1.83M
+265.6% vs year-ago quarter
Operating cash flow
$3.02M
+88.5% vs year-ago quarter
Free cash flow
$2.29M
+58.0% vs year-ago quarter
EPS
$0.20
+233.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
9.08M
+0.4% vs year-ago quarter
Net cash
$-3.59M
Q2 FY2026
Operating margin
12.6%
TTM
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- ICCC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Portland, ME
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 811641
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $7.2M | $10.4M | $7.6M | $5.5M | $6.4M |
| Operating income | $1.9M | $2.0M | -$57,956 | $20,075 | $569,562 |
| Net income | $1.8M | $1.9M | -$2.8M | -$139,748 | $501,880 |
| Diluted EPS | $0.20 | $0.21 | -$0.31 | -$0.02 | $0.06 |
| Operating cash flow | $3.0M | $3.6M | $482,541 | -$1.2M | $1.6M |
| Free cash flow | $2.3M | $3.4M | $310,235 | -$1.8M | $1.4M |
| Total assets | $46.6M | $44.1M | $42.5M | $45.7M | $42.5M |
| Total liabilities | $15.3M | $15.0M | $15.5M | $15.9M | $16.9M |
| Stockholders' equity | $31.4M | $29.1M | $27.1M | $29.8M | $29.9M |
| Cash and investments | $8.9M | $6.8M | $3.8M | $3.9M | — |
| Total debt | $12.4M | $12.8M | $13.2M | $13.6M | $14.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Oct 13, 2026 | Oct 12, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 9, 2026 | Jul 9, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 10, 2026 | Jun 4, 2026 |
All 795 ImmuCell Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.